Osstyn Sander, Rauwenhoff Johanne, Handels Ron, de Vugt Marjolein E, Evers Silvia, van Mastrigt Ghislaine A P G, van Heugten Caroline M
Department of Psychiatry and Neuropsychology and Alzheimer Center Limburg, School for Mental Health and Neuroscience (MHeNS), Maastricht University, Maastricht, The Netherlands.
Limburg Brain Injury Center, Maastricht, The Netherlands.
Int J Technol Assess Health Care. 2025 Feb 10;41(1):e10. doi: 10.1017/S0266462324004811.
Following acquired brain injury (ABI), individuals often experience anxiety and/or depressive symptoms. BrainACT is an adapted form of Acceptance and Commitment Therapy (ACT) tailored to this target group. The current study is a trial-based health-economic evaluation comparing BrainACT to a psychoeducation and relaxation control treatment.
An economic evaluation from a societal perspective was conducted in the Netherlands alongside a multicenter randomized controlled two-armed parallel trial including 72 participants. A cost-utility and cost-effectiveness analysis was conducted where incremental costs, quality-adjusted life-years (QALYs), and anxiety/depression (Hospital Anxiety and Depression Scale (HADS) score) were collected and presented over a 1-year follow-up period. Bootstrapping, scenario, and subgroup analyses were performed to test the robustness of the results.
The BrainACT arm reported non-significant lower total costs (incremental difference of €-4,881; bootstrap interval €-12,139 to €2,330) combined with significantly decreased anxiety/depression (HADS) (3.2; bootstrap intervals 0.7-5.7). However, the total QALYs were non-significantly lower (-0.008; bootstrap interval -0.060 to 0.042) for BrainACT. The probability of the intervention being cost-effective was 86 percent at a willingness-to-accept threshold of €50,000/QALY. The scenario and subgroup analyses confirmed the robustness of the results.
BrainACT may be a more cost-effective alternative to a psychoeducation and relaxation intervention for anxiety and/or depressive symptoms following ABI. Despite limitations, BrainACT appears to be a promising addition to treatment options in the Netherlands. Further research is needed to validate these findings, and consideration should be given to implementing BrainACT in Dutch clinical settings with ongoing monitoring.
获得性脑损伤(ABI)后,个体常常会出现焦虑和/或抑郁症状。BrainACT是一种针对该目标群体改编的接纳与承诺疗法(ACT)。本研究是一项基于试验的卫生经济评估,将BrainACT与心理教育及放松对照治疗进行比较。
在荷兰从社会角度进行了一项经济评估,同时开展了一项多中心随机对照双臂平行试验,纳入72名参与者。进行了成本效用和成本效益分析,收集了1年随访期内的增量成本、质量调整生命年(QALY)以及焦虑/抑郁(医院焦虑抑郁量表(HADS)评分)并进行呈现。进行了自抽样、情景分析和亚组分析以检验结果的稳健性。
BrainACT组报告总成本无显著降低(增量差异为-4881欧元;自抽样区间为-12139欧元至2330欧元),但焦虑/抑郁(HADS)显著降低(3.2;自抽样区间为0.7至5.7)。然而,BrainACT组的总QALY无显著降低(-0.008;自抽样区间为-0.060至0.042)。在每QALY愿意接受的阈值为50000欧元时,干预具有成本效益的概率为86%。情景分析和亚组分析证实了结果的稳健性。
对于ABI后出现的焦虑和/或抑郁症状,BrainACT可能是比心理教育及放松干预更具成本效益的替代方案。尽管存在局限性,但BrainACT在荷兰似乎是一种有前景的治疗选择补充。需要进一步研究来验证这些发现,并且应该考虑在荷兰临床环境中实施BrainACT并进行持续监测。